Data WHO/UNICEF & CDC · 21 October 2026 How grades work · Changelog · Corrections

Open Source Medicine Foundation

Saint Lucia

Coverage to 2025 · cases to 2025

Vaccination rates and reported vaccine-preventable disease in Saint Lucia, with a data-quality grade on every series.

← All countries · Americas

86%
MCV1
2025 · WHO/UNICEF estimate
84%
DTP3
2025 · WHO/UNICEF estimate
84%
IPV complete
2025 · WHO/UNICEF estimate
84%
HepB3
2025 · WHO/UNICEF estimate
0
Measles cases
2025 reported
0
Pertussis (whooping cough) cases
2025 reported

Two kinds of number live on this page. Coverage is the share of the target cohort vaccinated, as estimated by WHO and UNICEF each July from the country's reports, surveys and other evidence, shown beside what the country itself reported. Reported cases are what the national surveillance system sent to WHO; they are a floor, not a count of infections. Every row carries a grade; hover or focus it for the reason, or read how grades are assigned.

Vaccination coverage

Vaccination coverage by antigen, latest WHO/UNICEF estimate, country-reported figure, trend since 2000 and data-quality grade
VaccineLatest estimateCountry-reportedTrend since 2000Data quality
BCGTuberculosis vaccine at birth94%2025 · WHO/UNICEF estimate93.7%BCG coverage: 2000 to 2025, latest 94% in 2025, lowest 81%, highest 99%.B · good
DTP1First dose of diphtheria-tetanus-pertussis90%2025 · WHO/UNICEF estimate90.3%DTP1 coverage: 2000 to 2025, latest 90% in 2025, lowest 76%, highest 99%.B · good
DTP3Third dose of diphtheria-tetanus-pertussis (the WHO benchmark of a working programme)84%2025 · WHO/UNICEF estimate84.4%DTP3 coverage: 2000 to 2025, latest 84% in 2025, lowest 70%, highest 99%.A · strong
IPV1First dose of inactivated polio vaccine90%2025 · WHO/UNICEF estimate90.3%IPV1 coverage: 2015 to 2025, latest 90% in 2025, lowest 21%, highest 99%.B · good
IPV completeInactivated polio vaccine, complete primary series84%2025 · WHO/UNICEF estimate84.4%IPV complete coverage: 2023 to 2025, latest 84% in 2025, lowest 84%, highest 99%.C · weak
MCV1First dose of measles-containing vaccine86%2025 · WHO/UNICEF estimate85.7%MCV1 coverage: 2000 to 2025, latest 86% in 2025, lowest 77%, highest 99%.B · good
MCV2Second dose of measles-containing vaccine78%2025 · WHO/UNICEF estimate77.8%MCV2 coverage: 2000 to 2025, latest 78% in 2025, lowest 22%, highest 95%.A · strong
RCV1First dose of rubella-containing vaccine86%2025 · WHO/UNICEF estimate85.7%RCV1 coverage: 2000 to 2025, latest 86% in 2025, lowest 77%, highest 99%.A · strong
HepB3Third dose of hepatitis B vaccine84%2025 · WHO/UNICEF estimate84.4%HepB3 coverage: 2002 to 2025, latest 84% in 2025, lowest 14%, highest 99%.A · strong
HepB birthHepatitis B birth dose within 24 hours90%2025 · WHO/UNICEF estimate89.8%HepB birth coverage: 2018 to 2025, latest 90% in 2025, lowest 17%, highest 94%.B · good
Hib3Third dose of Haemophilus influenzae type b vaccine84%2025 · WHO/UNICEF estimate84.4%Hib3 coverage: 2002 to 2025, latest 84% in 2025, lowest 14%, highest 99%.A · strong
PCV1Pneumococcal conjugate vaccine, first dose—% · Administrative (country-reported)—too few pointsno data
PCV completePneumococcal conjugate vaccine, final dose of the schedule—% · Administrative (country-reported)—too few pointsno data
RotaCRotavirus vaccine, complete series—% · Administrative (country-reported)—too few pointsno data
Yellow feverYellow fever vaccine (countries at risk)—% · Administrative (country-reported)—too few pointsno data
MenAMeningococcal A conjugate (meningitis belt)—% · Administrative (country-reported)—too few pointsno data
JEJapanese encephalitis vaccine (countries at risk)—% · Administrative (country-reported)—too few pointsno data
TCVTyphoid conjugate vaccine—% · Administrative (country-reported)—too few pointsno data
PABProtection at birth against neonatal tetanus (maternal tetanus doses)—% · Administrative (country-reported)—too few pointsno data
HPV dose 1, girlsHPV programme coverage, first dose, girls89%2025 · WHO/UNICEF estimate—HPV dose 1, girls coverage: 2019 to 2025, latest 89% in 2025, lowest 52%, highest 91%.D · poor
HPV complete, girlsHPV programme coverage, complete series, girls89%2025 · WHO/UNICEF estimate—HPV complete, girls coverage: 2019 to 2025, latest 89% in 2025, lowest 42%, highest 91%.D · poor
HPV dose 1, boysHPV programme coverage, first dose, boys93%2025 · WHO/UNICEF estimate—HPV dose 1, boys coverage: 2019 to 2025, latest 93% in 2025, lowest 49%, highest 93%.D · poor

Reported vaccine-preventable disease

Reported cases and incidence by disease, latest year, trend since 2000 and data-quality grade
DiseaseReported casesIncidence rateTrend since 2000Data quality
Measles all countries · vaccine evidence020250per 1,000,000 total populationMeasles reported cases: 2000 to 2025, latest 0 in 2025, lowest 0, highest 0.B · good
Rubella all countries · vaccine evidence020250per 1,000,000 total populationRubella reported cases: 2001 to 2025, latest 0 in 2025, lowest 0, highest 0.B · good
Congenital rubella syndrome all countries · vaccine evidence020250per 10,000 live birthsCongenital rubella syndrome reported cases: 2001 to 2025, latest 0 in 2025, lowest 0, highest 0.B · good
Mumps all countries · vaccine evidence020250per 1,000,000 total populationMumps reported cases: 2001 to 2025, latest 0 in 2025, lowest 0, highest 73.B · good
Pertussis (whooping cough) all countries · vaccine evidence020250per 1,000,000 total populationPertussis (whooping cough) reported cases: 2000 to 2025, latest 0 in 2025, lowest 0, highest 8.A · strong
Diphtheria all countries · vaccine evidence020250per 1,000,000 total populationDiphtheria reported cases: 2000 to 2025, latest 0 in 2025, lowest 0, highest 0.B · good
Tetanus (total) all countries · vaccine evidence020250per 1,000,000 total populationTetanus (total) reported cases: 2000 to 2025, latest 0 in 2025, lowest 0, highest 1.A · strong
Neonatal tetanus all countries · vaccine evidence020250per 1,000 live birthsNeonatal tetanus reported cases: 2000 to 2025, latest 0 in 2025, lowest 0, highest 0.B · good
Polio (paralytic) all countries · vaccine evidence020250per 1,000,000 <15 populationPolio (paralytic) reported cases: 2000 to 2025, latest 0 in 2025, lowest 0, highest 0.C · weak
Yellow fever all countries · vaccine evidence020250per 1,000,000 total populationYellow fever reported cases: 2000 to 2025, latest 0 in 2025, lowest 0, highest 0.B · good
Japanese encephalitis all countries · vaccine evidence020060per 1,000,000 total populationtoo few pointsno data
Invasive meningococcal disease all countries · vaccine evidence020250per 1,000,000 total populationInvasive meningococcal disease reported cases: 2020 to 2025, latest 0 in 2025, lowest 0, highest 0.D · poor
Typhoid all countries · vaccine evidence020250per 1,000,000 total populationTyphoid reported cases: 2018 to 2025, latest 0 in 2025, lowest 0, highest 0.C · weak

National schedule (latest WHO listing)

Show the schedule (43 rows)
National immunization schedule
VaccineDoseAgeTarget groupComment
BCGBCG (Baccille Calmette Guérin) vaccine1M2General/routineSingle dose administered at M2 as per the routine schedule
COVID19COVID-19 vaccine1AdultsAll adults, all older adults
COVID19COVID-19 vaccine1General/routineAll children and adolescents
COVID19COVID-19 vaccine1Health workersHealth and care workers
COVID19COVID-19 vaccine1Pregnant womenPregnant women
COVID19COVID-19 vaccine1Risk group(s)Children and adolescents with chronic conditions, adults with chronic conditions, older adults with chronic conditions
DTWPDTwP (Whole cell) vaccine4M18General/routinegiven to children M18 and Y5 as per the rouine schedule
DTWPDTwP (Whole cell) vaccine5Y5General/routinegiven to children M18 and Y5 as per the rouine schedule
DTWPHIBHEPBDTwP-Hib-HepB (Whole cell) vaccine1M2General/routineChildren M2 - M6
DTWPHIBHEPBDTwP-Hib-HepB (Whole cell) vaccine2M4General/routineChildren M2 - M6
DTWPHIBHEPBDTwP-Hib-HepB (Whole cell) vaccine3M6General/routineChildren M2 - M6
HEPB_ADULTAdult Hepatitis B (HepB) vaccine11st contactAdultsAdults including Healthcare Workers (on request)
HEPB_ADULTAdult Hepatitis B (HepB) vaccine11st contactHealth workersAdults including Healthcare Workers (on request)
HEPB_ADULTAdult Hepatitis B (HepB) vaccine2+W6AdultsAdults including Healthcare Workers (on request)
HEPB_ADULTAdult Hepatitis B (HepB) vaccine2+W6Health workersAdults including Healthcare Workers (on request)
HEPB_ADULTAdult Hepatitis B (HepB) vaccine3+M5AdultsAdults including Healthcare Workers (on request)
HEPB_ADULTAdult Hepatitis B (HepB) vaccine3+M5Health workersAdults including Healthcare Workers (on request)
HEPB_PEDIATRICPediatric Hepatitis B (HepB) vaccine1BGeneral/routineHepB- Birth dose is given within 48 hours
HPV4HPV-4 (Human papillomavirus 4-valent) vaccine1Y10-Y12HPV administered to females and malesMales and Females in Grade Six
INFLUENZA_ADULTAdult seasonal influenza vaccine1>Y18Adultsand older persons 60+
INFLUENZA_ADULTAdult seasonal influenza vaccine1Health workersHealth and care workers
INFLUENZA_ADULTAdult seasonal influenza vaccine1Pregnant womenPregnant women
INFLUENZA_ADULTAdult seasonal influenza vaccine1Risk group(s)Adults with chronic conditions, residents living in long-term care facilities
INFLUENZA_PEDIATRICPediatric seasonal influenza vaccine1>=M6General/routine
INFLUENZA_PEDIATRICPediatric seasonal influenza vaccine1Risk group(s)Children with chronic conditions
IPVIPV (Inactivated polio vaccine)1M2General/routineOnly two IPV doses are given at M2 and M6 as part of the routine schedule
IPVIPV (Inactivated polio vaccine)2M6General/routineOnly two IPV doses are given at M2 and M6 as part of the routine schedule
MMRMMR (Measles, mumps and rubella) vaccine1M12General/routineAlso given to adolecents and adults with no evidence of vaccination history
MMRMMR (Measles, mumps and rubella) vaccine1Risk group(s)Adolecents and adults with no evidence of vaccination history
MMRMMR (Measles, mumps and rubella) vaccine2M18General/routineAlso given to adolecents and adults with no evidence of vaccination history
OPVOPV (Oral polio vaccine)2M4General/routineChildren M2 to Y12
OPVOPV (Oral polio vaccine)4M18General/routineChildren M2 to Y12
OPVOPV (Oral polio vaccine)5Y5General/routineChildren M2 to Y12
OPVOPV (Oral polio vaccine)6Y10-Y12General/routineChildren M2 to Y12
PCV13PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine1M2Risk group(s)Infants with chronic diseases only
PCV13PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine2M4Risk group(s)Infants with chronic diseases only
PCV13PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine3M6Risk group(s)Infants with chronic diseases only
PPV23PPV-23 (Pneumococcal polysaccharide 23-valent) vaccine4Y2-Y18Risk group(s)Older children with chronic diseases
TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine1AdultsAdults
TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine1Risk group(s)Adults with no vaccine records upon request
TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine6Y10-Y12General/routineGrade-six students, adults with no vaccine records upon request
VARICELLAVaricella vaccine1Risk group(s)Based on request
YFYF (Yellow fever) vaccine11st contactTravellersAdult travellers

Compare schedules across 31 countries on the schedule hub.

Data and sources

Coverage figures are WHO/UNICEF estimates unless a row says otherwise; reported cases are what national authorities sent to WHO and undercount true infections. Each series carries a data-quality grade that says why.

Cite this page. Saint Lucia. Vaccine Data Navigator, Open Source Medicine Foundation. Built 21 October 2026 from WHO/UNICEF (WIISE) exports and CDC SchoolVaxView. https://vaccinedatanavigator.org/disease-risk/countries/lca.html

Report an error